Lumasiran [CAS 1834610-13-7]

Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1) [1][2].

[1834610-13-7]

C530H712F10N173O320P43S6

16339

[Lumasiran]

Glycolate Oxidase; Small Interfering RNA (siRNA)

98.77

H2O : 100 mg/mL (ultrasonic)

-20°C (Powder, sealed storage, away from moisture)

Blue Ice